GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia

Phase 4

Terminated

Conditions: Prostatic Hyperplasia

Interventions: Drug: Dutasteride/Tamsulosin

First Posted Date: 2012-08-28

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 59

Registration Number: NCT01673490

Locations: 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

Phase 1

Completed

Conditions: Anaemia

Interventions: Drug: GSK1278863
Drug: Placebo

First Posted Date: 2012-08-28

Last Posted Date: 2017-06-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 49

Registration Number: NCT01673555

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: FF, 50 mcg
Drug: FF, 100 mcg
Drug: FF, 200 mcg
Drug: FF, 250 mcg

First Posted Date: 2012-08-20

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT01669070

Locations: 🇳🇱
GSK Investigational Site, Groningen, Netherlands

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Phase 3

Terminated

Conditions: Epilepsy

Interventions: Drug: retigabine/ezogabine

First Posted Date: 2012-08-20

Last Posted Date: 2020-10-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4

Registration Number: NCT01668654

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Pharmacokinetic Study of 4 mg Nicotine Lozenge.

Phase 2

Completed

Conditions: Smoking Cessation

Interventions: Drug: nicotine

First Posted Date: 2012-08-20

Last Posted Date: 2015-01-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT01669122

Locations: 🇮🇳
Lambda Therapeutic Research Ltd, Ahmedabad, Gujarat, India

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: GSK Biologicals' investigational TB vaccine GSK 692342

First Posted Date: 2012-08-20

Last Posted Date: 2019-03-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT01669096

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing

Phase 1

Completed

Conditions: Embryo Transfer

Interventions: Drug: GSK557296 10 mg
Drug: GSK557296 150 mg
Drug: GSK557296 dose 4
Drug: GSK557296 dose 3

First Posted Date: 2012-08-20

Last Posted Date: 2017-06-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT01669083

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug: GSK1322322 1000 mg containing radioactive 14C-GSK1322322

First Posted Date: 2012-08-13

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 5

Registration Number: NCT01663389

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.

First Posted Date: 2012-08-13

Last Posted Date: 2017-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01663714

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Investigational H9N2 vaccine GSK2654911A
Biological: Investigational H9N2 vaccine GSK2654909A
Biological: Placebo

First Posted Date: 2012-08-07

Last Posted Date: 2018-06-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 422

Registration Number: NCT01659086

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy